UNSPSC 51314379: Promethazine/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314379 Promethazine/pseudoephedrine is a Commodity code, but the recent opportunities tagged under it show significant scope misalignment — the solicitations are for naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products via cooperative purchasing, and direct-to-manufacturer prescription programs, none of which match the specific code's focus on a single branded or generic respiratory combination drug. State and local buyers are using this code to procure a much broader range of pharmaceutical products and pharmacy benefit management services, including emergency-response naloxone kits, bulk OTC and generic pharmaceutical inventories through cooperative purchasing alliances, and exploratory direct contracting with pharmaceutical manufacturers to bypass traditional pharmacy benefit managers and wholesalers.

The issuing-body mix reflects state health agencies, counties, and cooperative purchasing consortia spanning multiple states. Seminole County, Florida posted an IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with a response deadline of July 26, 2023 (note: the posted date of June 30, 2026 conflicts with the stated due date; the source contains a date inconsistency). The Texas Health and Human Services Commission issued an RFI on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program aimed at streamlining prescription fulfillment and cost management outside traditional PBM and GPO channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP on January 20, 2026 due March 26, 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson) and to pay a 3 percent administrative fee. Geographic activity spans Florida, Texas, and the MMCAP consortium states (Minnesota and Oregon). The code shows limited recent relevant activity — the mismatch between the Commodity code's nominal scope (a specific combination antihistamine/decongestant formulation) and the actual solicitations (broad pharmaceutical procurement, emergency-response supplies, and pharmacy contracting models) indicates that this code is neither consistently applied nor actively pursued for its intended product line in state and local procurement.